Compare Ecopetrol SA (EC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Mesoblast Limited — how do they compare? Ecopetrol SA trades at $15.94 (market cap $30.44B), while Mesoblast Limited trades at $18.61 (market cap $2.31B). The key difference: Ecopetrol SA is far larger — about 13.2× Mesoblast Limited's market cap, and Ecopetrol SA pays a 4.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EC | MESO | |
|---|---|---|
Market Cap | $30.44B | $2.31B |
Sector | Energy | Technology |
52-Week High | $16.58 | $20.96 |
52-Week Low | $8.29 | $11.35 |
Enterprise Value | $58.23B | $2.32B |
Dividend Yield | 4.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $15.93, down 1.42% with mixed technical signals showing bullish moving averages but bearish oscillators. The company maintains solid profitability with 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6B in 2022 to $119.7B in 2025. Recent developments include a collective bargaining agreement with workers and upcoming Q2 2026 earnings release on August 3, 2026.
While valuation appears reasonable with P/E of 11.39, declining revenue trends and recent earnings misses pose challenges. Analyst consensus is cautious with 54.55% hold rating and $14.63 price target below current levels. Key risks include oil price volatility and execution challenges in a competitive energy sector.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
